表紙
市場調査レポート

腎癌治療薬:産業分析・R&D動向・世界市場の推移と予測 (2015-2025年)

Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025

発行 Visiongain Ltd 商品コード 341891
出版日 ページ情報 英文 137 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.02円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
腎癌治療薬:産業分析・R&D動向・世界市場の推移と予測 (2015-2025年) Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025
出版日: 2015年10月08日 ページ情報: 英文 137 Pages
概要

世界の腎臓癌治療薬の市場規模は2019年には56億ドルの規模に成長すると予測されています。

当レポートでは、世界の腎臓癌治療薬市場の現状と見通しについて調査し、腎癌、腎癌治療、腎癌治療薬の定義と概要、主な薬剤および製薬会社のプロファイル、薬剤の区分および地域別の市場規模の推移と予測、開発パイプラインの状況、SWOT分析、専門家による見解などをまとめています。

第1章 調査概要

第2章 イントロダクション:腎癌治療

  • 腎癌とは?
  • 腎癌の薬剤治療
  • 腎癌治療市場の定義

第3章 主要腎癌治療薬・主要薬剤のプロファイルおよび予測

  • 市場をリードする血管新生阻害剤
    • Sutent (sunitinib) - Pfizer
    • Nexavar (sorafenib) - Bayer/Onyx
    • Votrient (pazopanib) - Novartis
    • Inlyta (axitinib) - Pfizer
  • mTOR阻害剤:強力な競争相手
    • Afinitor/Votubia (everolimus) - Novartis
    • Torisel (temsirolimus) - Pfizer
  • モノクローナル抗体:変化をもたらす薬剤
    • Avastin (bevacizumab) - Roche
  • 免疫療法:注目の市場
    • Proleukin (aldesleukin) - Novartis/Prometheus Laboratories
  • 主要企業
    • Pfizer
    • Novartis
    • Roche
    • Bayer Healthcare・Onyx Pharmaceuticals
    • その他の興味深い企業
      • Exelixis・Bristol-Myers Squibb・Merck・Cerulean Pharma

第4章 世界の腎癌抗癌剤市場の展望・予測

  • 世界市場の実績
  • 主な薬剤治療
  • 世界の収益規模の推移と予測:市場シェアの変化
  • 主な抗癌剤の市場の推移と予測
    • 血管新生阻害剤:現在の市場をリード
    • モノクローナル抗体:強力な競争相手のAvastin
    • 重要市場:mTOR阻害剤
    • サマリー:血管新生阻害剤・mTOR阻害剤が市場をリード
  • 市場成長推進因子・阻害因子

第5章 主要国市場の予測

  • 市場規模実績の地域別内訳
  • 世界市場の推移と予測:地域別
  • 米国市場の推移と予測
    • 成長推進因子・阻害因子
  • EU市場の推移と予測
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
  • 日本市場の推移と予測
  • 新興市場:BRIC市場の推移と予測
    • 中国
    • ブラジル
    • ロシア
    • インド

第6章 腎癌治療薬産業:R&Dパイプラインの分析

  • 開発中の標的治療薬
    • Lenvima (lenvatinib) - エーザイ
    • Cometriq (cabozantinib) - Exelixis
    • Dovitinib (TKI258) - Novartis
    • Linifanib (ABT-869) - Abbott Laboratories
    • Tivozanib - Aveo Pharmaceuticals
    • BEZ235 - Novartis
    • Tivantinib (ARQ197) - 第一三共/ArQule
    • Cediranib (AZD2171/Recentin) - AstraZeneca
  • 開発中の免疫療法
    • Opdivo (nivolumab) - Bristol-Myers Squibb
    • AGS-003 - Argos Therapeutics
    • IMA901- Immatics Biotechnologies/Roche
    • TVI-Kidney-1 - TVAX Biomedical
    • Keytruda (pembrolizumab/MK3475) - Merck & Co
    • Atezolizumab (MPDL3280A) - Roche
    • Avelumab (MSB0010718C) - Merck
  • 開発中のモノクローナル抗体
    • TRC105 - Tracon Pharma
    • RENCAREX (girentuximab) - WILEX AG
    • Varlilumab (CDX-1127/ Anti-CD27) - Celldex Therapeutics
    • ASONEP (sonepcizumab/LT1009) - Lpath Inc
  • 開発中の新しい抗癌剤
    • CRLX101 - Cerulean Pharma
    • Entinostat (SNDX-275/MS-275) - Syndax Pharmaceuticals

第7章 定性分析

  • SWOT分析
  • 市場機会・脅威

第8章 専門家へのインタビュー

第9章 総論

図表

目次
Product Code: PHA0071

Kidney Cancer Therapies - Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities

Are you interested in the future of renal cancer treatments? Our new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D and opportunities, seeing commercial prospects.

Visiongain's report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and sales are possible for those cancer treatments.

Read on, then, to explore renal cancer therapy and see what future revenues that expanding pharma market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions

With our new study you explore prospects for companies developing, producing and marketing drugs for treating cancer of the human kidneys. See present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing prospects. Also get 51 tables, 38 charts and two interviews with companies.

So avoid missing out on original data and discussions to help your work.

image1

image2

R&D and opportunities for sales growth - explore trends and forecasts, staying ahead

Our study's purpose is to help your research, analyses and decisions on those renal therapies, also benefiting your authority and reputation for insight.

The future looks promising for pharma companies treating those cancers. Discover the progress and gains possible there, avoiding struggles to find business information you need. See, from 2015, how patients, healthcare providers and companies can benefit.

Visiongain's analysis shows how the industry for renal cancer treatments evolves. New products enter that market and novel drug candidates reach late-stage clinical trials. Discover what future revenues are possible in that expanding pharma sector.

Although no single study covers everything, the following sections show how our new investigation benefits your work.

image3

image4

Forecasts covering the overall world market and segments for treating kidney cancer

Discover in our new report forecasted world revenue to 2025 for those anticancer medicines - existing, emerging and expected drugs.

You also gain individual revenue predictions to 2025 for five submarkets at world level. See what is possible for these therapeutic classes:

  • Angiogenesis inhibitors
  • mTOR inhibitors
  • Monoclonal antibodies (mAbs)
  • Immunotherapies
  • Generics and other products.

Where lie the best sales potentials? With our analysis you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and prospects.

See how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a growing incidence of renal cancer, the demand for better treatments will continue to bolster that industry and market.

You also find sales predictions by product, exploring how they can succeed.

image5

image6

Predictions of leading products' sales - what is possible for those cancer-treating drugs?

How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of these eight brands:

  • Sutent (sunitinib)
  • Nexavar (sorafenib)
  • Votrient (pazopanib)
  • Inlyta (axitinib)
  • Afinitor (everolimus)
  • Torisel (temsirolimus)
  • Avastin (bevacizumab)
  • Proleukin (aldesleukin).

There you find how high sales can go, finding medicines and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds. Our work also shows you geographical predictions, by country.

National markets - what outlooks for kidney cancer drug revenues?

Advances in the biopharma industry and market expand the use of drugs to treat renal cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, the United Kingdom (UK), Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).

That way, you assess countries with highest revenues and potential growth. Explore outlooks for treating that disease, including patients' and healthcare providers' needs.

You also examine developments leading to novel treatments.

R&D for those cancer therapies - developmental trends, innovations and progress

In our study you investigate that oncology - research and development on kidney cancer. You examine technological advances, seeing clinical progress and finding what it means.

Discussions appear for 21 drug candidates in the pipeline, including these agents:

  • Lenvima (lenvatinib, Eisai)
  • Opdivo (nivolumab, Bristol-Myers Squibb)
  • Keytruda (pembrolizumab, Merck)
  • Cometriq (cabozantinib, Exelixis)
  • Tivantinib (ARQ197, ArQule/Daiichi Sankyo)
  • IMA901 (Immatics Biotechnologies/Roche)
  • Atezolizumab (MPDL3280A/Roche).

In particular, checkpoint inhibitors can bring a new era for immunotherapy and make a difference in long-term treatment success for renal cancer patients.

R&D for treating renal cancer holds strength, variety and promise. That work gains momentum from rising disease prevalence and other forces making treatments for those kidney disorders more prominent in healthcare.

Events and changes affecting companies treating kidney cancer - see what the future holds

Explore other issues, too, including these forces shaping that industry and market:

  • Rising prevalence of cancers
  • Effect of treatment cost on sales expansion
  • Patent expiries approaching - the threat of generics for novel drug producers
  • Combination medicines and targeted therapies
  • Regulatory affairs - outlook for drug development and approval.

You also gain SWOT analysis, assessing what drives and restrains that pharma market.

See, then, what is possible for big pharma companies and specialists in biological drugs and related biotechnologies.

Leading companies and overall 2019 market value - what revenues are possible?

Our work predicts the world market for kidney cancer-treating drugs will reach $5.6bn in 2019. That industry will achieve revenue expansion from 2015 to 2025. With our analysis you discover how high sales can go, seeing what is possible for those drug producers.

That way you assess what companies hold most potential. For those therapies, explore pharmaceutical developers, producers and marketers, including these firms:

  • Pfizer
  • Novartis
  • Roche
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • Exelixis
  • Cerulean Pharma
  • Merck & Co.

You also see interviews with WILEX and TVAX Biomedical. Discover what the future holds for organisations treating those renal disorders, finding what participants say and do.

7 ways Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:

  • Revenues for kidney cancer treatments to 2025 - assess that overall world market's potential, seeing scope for investments, developments and marketing
  • Submarket revenues to 2025 covering 5 therapeutic categories - explore segments, seeing their sales outlooks from 2015
  • Leading products' sales to 2025 - discover predicted revenues of 8 brands, seeing how well those medicines can compete and succeed
  • National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
  • R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinions - examine participants in that rising market, and gain two interviews, helping you stay ahead and benefit your influence
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.

Gain predictions for treating kidney cancer, getting information to help you stay ahead

With our independent analyses you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how you could save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study. Our investigation shows data, trends, opportunities and forecasts for that expanding drugs market. So avoid missing out - please get our new report here now.

Table of Contents

1. Report Overview

  • 1.1 Global Market Overview of the Renal Cancer Treatment Market
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methods of the Study
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. An Introduction to Renal Cancer Treatments

  • 2.1 What is Renal Cancer?
  • 2.2 Renal Cancer Drug Treatments
  • 2.3 Defining the Renal Cancer Treatment Market

3. Leading Renal Cancer Drugs and Leading Companies: Profiles and Forecasts from 2015-2025

  • 3.1 Angiogenesis Inhibitors Lead the Market
    • 3.1.1 Sutent (sunitinib) - Pfizer
    • 3.1.2 Nexavar (sorafenib) - Bayer/Onyx
    • 3.1.3 Votrient (pazopanib) - Novartis
    • 3.1.4 Inlyta (axitinib) - Pfizer
  • 3.2 mTOR Inhibitors Are Strong Competitors
    • 3.2.1 Afinitor/Votubia (everolimus) - Novartis
    • 3.2.2 Torisel (temsirolimus) - Pfizer
  • 3.3 Monoclonal Antibodies: One Drug Makes a Difference
    • 3.3.1 Avastin (bevacizumab) - Roche
  • 3.4 Immunotherapies: A Market to Watch
    • 3.4.1 Proleukin (aldesleukin) - Novartis/Prometheus Laboratories
  • 3.5 Leading Companies in the Renal Drug Treatment Market
    • 3.5.1 Pfizer: Current Market Leader
    • 3.5.2 Novartis: Building Up Strengths
    • 3.5.3 Roche: Expanding Blockbuster Avastin
    • 3.5.4 Bayer Healthcare and Onyx Pharmaceuticals
    • 3.5.5 Other Companies of Interest
    • 3.5.5.1 Exelixis, Bristol-Myers Squibb, Merck and Cerulean Pharma

4. Anti-Cancer Renal Treatments: World Market Outlook and Forecast 2015-2025

  • 4.1 The World Market for Renal Cancer Treatments in 2014
  • 4.2 Leading Renal Cancer Drug Treatments in 2014
  • 4.3 World Revenue Forecasts 2015-2025: Changing Market Shares for the Renal Cancer Treatment Market
  • 4.4 Leading Anti-Cancer Renal Treatment Submarkets 2015-2025
    • 4.4.1 Angiogenesis Inhibitors Lead the Current Market
    • 4.4.2 Monoclonal Antibodies: Avastin is a Strong Competitor
    • 4.4.3 An Important Submarket: mTOR Inhibitors
    • 4.4.4 Summary: Angiogenesis Inhibitors and mTOR Inhibitors Lead the Market in 2015
  • 4.5 Drivers and Restraints of the Renal Cancer Treatment Market 2015-2025
    • 4.5.1 Drivers of the Renal Cancer Treatment Market
    • 4.5.2 Restraints of the Renal Cancer Treatment Market

5. Leading National Markets for the Renal Cancer Treatment Market 2015-2025

  • 5.1 Regional Breakdown of the World Renal Cancer Treatment Market 2014
  • 5.2 World Renal Cancer Treatment Market: Regional Forecasts 2015-2025
    • 5.2.1 How Will Regional Market Shares Change to 2025?
  • 5.3 The US Renal Cancer Treatment Market 2015-2025
    • 5.3.1 The US Renal Cancer Treatment Market: Drivers and Restraints
  • 5.4 The EU Renal Cancer Treatment Market 2015-2025
    • 5.4.1 The Renal Cancer Treatment Market in Germany to 2025
    • 5.4.2 The Renal Cancer Treatment Market in France to 2025
    • 5.4.3 The Renal Cancer Treatment Market in Italy to 2025
    • 5.4.4 The Renal Cancer Treatment Market in the UK to 2025
    • 5.4.5 The Renal Cancer Treatment Market in Spain to 2025
  • 5.5 The Japanese Renal Cancer Treatment Market
  • 5.6 The Renal Cancer Treatment Market in the Emerging Market: BRIC Market Forecast 2015-2025
    • 5.6.1 The Renal Cancer Treatment Market in China to 2025
    • 5.6.2 The Renal Cancer Treatment Market in Brazil to 2025
    • 5.6.3 The Renal Cancer Treatment Market in Russia to 2025
    • 5.6.4 The Renal Cancer Treatment Market in India to 2025

6. Renal Cancer Drugs Industry: R&D Pipeline Analysis

  • 6.1 Targeted Therapies in Development for the Treatment of Renal Cancer
    • 6.1.1 Lenvima (lenvatinib) - Eisai Inc
    • 6.1.2 Cometriq (cabozantinib) - Exelixis
    • 6.1.3 Dovitinib (TKI258) - Novartis
    • 6.1.4 Linifanib (ABT-869) - Abbott Laboratories
    • 6.1.5 Tivozanib - Aveo Pharmaceuticals
    • 6.1.6 BEZ235 - Novartis
    • 6.1.7 Tivantinib (ARQ197) - Daiichi Sankyo/ArQule
    • 6.1.8 Cediranib (AZD2171/Recentin) - AstraZeneca
  • 6.2 Immunotherapies in Development for the Treatment of Renal Cancer
    • 6.2.1 Opdivo (nivolumab) - Bristol-Myers Squibb
    • 6.2.2 AGS-003 - Argos Therapeutics
    • 6.2.3 IMA901- Immatics Biotechnologies/Roche
    • 6.2.4 TVI-Kidney-1 - TVAX Biomedical
    • 6.2.5 Keytruda (pembrolizumab/MK3475) - Merck & Co
    • 6.2.6 Atezolizumab (MPDL3280A) - Roche
    • 6.2.7 Avelumab (MSB0010718C) - Merck
  • 6.3 Monoclonal Antibody Therapies in Development for the Treatment of Renal Cancer
    • 6.3.1 TRC105 - Tracon Pharma
    • 6.3.2 RENCAREX (girentuximab) - WILEX AG
    • 6.3.3 Varlilumab (CDX-1127/ Anti-CD27) - Celldex Therapeutics
    • 6.3.4 ASONEP (sonepcizumab/LT1009) - Lpath Inc
  • 6.4 Novel Anti-Cancer Therapies in the Pipeline for Renal Cancer
    • 6.4.1 CRLX101 - Cerulean Pharma
    • 6.4.2 Entinostat (SNDX-275/MS-275) - Syndax Pharmaceuticals

7. Qualitative Analysis of the Renal Cancer Treatments Market, 2015-2025

  • 7.1 SWOT Analysis of the Renal Cancer Treatment Market
    • 7.1.1 Strengths and Weaknesses of the Market
    • 7.1.2 The Increasing Prevalence of Renal Cancer
    • 7.1.3 A Rise in Ageing Population
    • 7.1.4 Increasing Risk Factors: Obesity and Smoking
    • 7.1.5 The High Cost of Drug Treatments Will Limit Market Growth
    • 7.1.6 Important Patent Expiries Are Looming
  • 7.2 Opportunities and Threats
    • 7.2.1 Novel Therapies: The Rise of Immunotherapy
    • 7.2.2 Combination Therapies: An Opportunity to Improve on Existing Treatments
    • 7.2.3 Regulations: A Hindrance for Growth of the Market

8. Research Interviews

  • 8.1 Interview with Dr Paul Bevan, Head of R&D, WILEX, Munich, Germany
    • 8.1.1 RENCAREX: Possible First Adjuvant Treatment of RCC
  • 8.2 Interview with Gary Wood, PhD, Chief Science Officer, TVAX Biomedical, Kansas, USA
    • 8.2.1 Novel Immunotherapy Treatment for Renal Cancer
    • 8.2.2 The Challenges of Using New Therapies

9. Conclusions

  • 9.1 The Renal Cancer Treatment Market: World Outlook from 2015
  • 9.2 Growth Will Be Driven by an Increase in Demand
  • 9.3 The Global Renal Cancer Treatment Market Will Continue to be Dominated by the US and the EU
  • 9.4 Leading Renal Cancer Treatment Drug Companies
  • 9.5 The Future of the Renal Cancer Treatment Market

List of Tables

  • Table 1.1 Foreign Currency Exchange Rates: 2014 Average Exchange Rate to $US
  • Table 2.1 Main Subtypes of Renal Cell Carcinoma
  • Table 3.1 Sutent Revenue Forecast ($bn), 2014-2025
  • Table 3.2 Nexavar Revenue Forecast ($bn), 2014-2025
  • Table 3.3 Votrient Revenue Forecast ($bn), 2014-2025
  • Table 3.4 Inlyta Revenue Forecast ($bn), 2014-2025
  • Table 3.5 Afinitor Revenue Forecast ($bn), 2014-2025
  • Table 3.6 Torisel Revenue Forecast ($bn), 2014-2025
  • Table 3.7 Avastin Revenue Forecast ($bn), 2014-2025
  • Table 3.8 Proleukin Revenue Forecast ($bn), 2014-2025
  • Table 3.9 Leading Renal Cancer Drug Manufacturer Revenues, 2014
  • Table 3.10 Pfizer: Selected Recent Collaborations
  • Table 3.11 Avastin: Selected Recent Combination Trials
  • Table 4.1 Global Market for Renal Cancer Drug Treatments: Revenues ($bn) and Market Shares (%) by Class, 2014
  • Table 4.2 Top Five Renal Cancer Treatment Drugs by Revenue ($bn), 2014
  • Table 4.3 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2014-2019
  • Table 4.4 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2020-2025
  • Table 4.5 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Changing Market Shares (%), 2014-2025
  • Table 4.6 Angiogenesis Inhibitors Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 4.7 Monoclonal Antibodies Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 4.8 MTOR Inhibitors Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 4.9 Angiogenesis and mTOR Inhibitors Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
  • Table 4.10 Drivers and Restraints of the Renal Cancer Treatment Market 2015-2025
  • Table 5.1 Regional and National Breakdown of the Renal Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2014
  • Table 5.2 Forecast of Regional and National Renal Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2014-2019
  • Table 5.3 Forecast of Regional and National Renal Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2020-2025
  • Table 5.4 Forecast of Regional and National Renal Cancer Treatment Markets: Market Shares (%), 2014-2025
  • Table 5.5 Forecast of the US Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.6 Drivers and Restraints of the US Market, 2015-2025
  • Table 5.7 EU Market Shares (%), 2014-2025
  • Table 5.8 Forecast of the EU Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2019
  • Table 5.9 Forecast of the EU Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2020-2025
  • Table 5.10 Forecast of the German Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.11 Forecast of the French Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.12 Forecast of the Italian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.13 Forecast of the UK Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.14 Forecast of the Spanish Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.15 Forecast of the Japanese Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.16 Forecast of the BRIC Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.17 Forecast of the Chinese Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.18 Forecast of the Brazilian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.19 Forecast of the Russian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.20 Forecast of the Indian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 6.1 Targeted Therapies in Development for Renal Cancer
  • Table 6.2 Lenvima: Target Molecules for Inhibition
  • Table 6.3 Immunotherapy Treatments in Development for Renal Cancer
  • Table 6.4 Monoclonal Antibody Treatments in Development for Renal Cancer
  • Table 6.5 Novel Treatments in Development for Renal Cancer
  • Table 7.1 Strengths and Weaknesses of the Renal Cancer Treatment Market, 2015-2025
  • Table 7.2 Opportunities and Threats in the Renal Cancer Treatment Market, 2015-2025
  • Table 9.1 Renal Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, and 2025
  • Table 9.2 Renal Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, and 2025

List of Figures

  • Figure 1.1 Global Renal Cancer Treatment Market Segmentation Overview, 2014
  • Figure 3.1 Sutent Revenue Forecast ($bn), 2014-2025
  • Figure 3.2 Nexavar Revenue Forecast ($bn), 2014-2025
  • Figure 3.3 Votrient Revenue Forecast ($bn), 2014-2025
  • Figure 3.4 Inlyta Revenue Forecast ($bn), 2014-2025
  • Figure 3.5 Afinitor Revenue Forecast ($bn), 2014-2025
  • Figure 3.6 Torisel Revenue Forecast ($bn), 2014-2025
  • Figure 3.7 Avastin Revenue Forecast ($bn), 2014-2025
  • Figure 3.8 Proleukin Revenue Forecast ($bn), 2014-2025
  • Figure 4.1 Global Market for Renal Cancer Treatment Drugs: Market Shares by Class (%), 2014
  • Figure 4.2 Top Five Renal Cancer Treatment Drugs by Revenue: Market Shares (%), 2014
  • Figure 4.3 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Market Sizes ($bn), 2014-2025
  • Figure 4.4 Global Market for Renal Cancer Treatment Drugs by Class: Market Shares (%), 2019
  • Figure 4.5 Global Market for Renal Cancer Treatment Drugs by Class: Market Shares (%), 2025
  • Figure 4.6 Angiogenesis Inhibitors Forecast: Revenue ($bn), 2014-2025
  • Figure 4.7 Monoclonal Antibodies Forecast: Revenue ($bn), 2014-2025
  • Figure 4.8 MTOR Inhibitors Forecast: Revenue ($bn), 2014-2025
  • Figure 4.9 Angiogenesis and mTOR Inhibitors Forecast: Revenue ($bn), 2014-2025
  • Figure 5.1 Regional and National Breakdown of the Renal Cancer Treatment Market: Market Shares (%), 2014
  • Figure 5.2 Forecast of Regional and National Renal Cancer Treatment Markets: Market Sizes ($bn), 2014-2025
  • Figure 5.3 Forecast Regional and National Renal Cancer Treatment Markets: Market Shares (%), 2019
  • Figure 5.4 Forecast Regional and National Renal Cancer Treatment Markets: Market Shares (%), 2025
  • Figure 5.5 Forecast of the US Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.6 EU Market for Renal Cancer Treatment by Leading Country (%), 2014
  • Figure 5.7 Forecast of the EU Renal Cancer Treatment Market, Market Sizes ($bn), 2014-2025
  • Figure 5.8 Forecast of the German Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.9 Forecast of the French Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.10 Forecast of the Italian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.11 Forecast of the UK Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.12 Forecast of the Spanish Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.13 Forecast of the Japanese Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.14 Forecast of the BRIC Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.15 Forecast of the Chinese Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.16 Forecast of the Brazilian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.17 Forecast of the Russian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 5.18 Forecast of the Indian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
  • Figure 9.1 Anti-Cancer Renal Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2014, 2019, and 2025
  • Figure 9.2 Renal Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2014, 2019, and 2025

Companies Listed

  • American Cancer Society
  • Amgen
  • Argos Therapeutics
  • ArQule
  • ASCO (American Society of Clinical Oncology)
  • Astellas
  • AstraZeneca
  • Aveo Pharmaceuticals
  • Bayer Healthcare
  • Brazilian Unified Health System (SUS, Sistema Único de SaÚde)
  • Bristol-Myers Squibb
  • Cancer Research UK
  • Celldex Therapeutics
  • Cerulean Pharma
  • Cetus Corporation
  • Chiron Corporation
  • CHMP (Committee for Medicinal Products for Human Use)
  • Commission de la Transparence
  • Daiichi Sankyo Group
  • DMC (Data Monitoring Committee)
  • Eddingpharm
  • Eisai Co
  • Eisai Inc (US subsidiary of Eisa Co)
  • EMA (European Medicines Agency)
  • European Commission
  • European Organisation for Research and Treatment and Cancer (EORTC)
  • Exelixis
  • FDA (US Food and Drug Administration)
  • French National Authority for Health
  • GSK
  • Immatics Biotechnologies
  • Kyowa Hakko Kirin
  • Lpath
  • Medarex
  • Merck & Co.
  • MHLW (Ministry of Health, Labour, and Welfare)
  • Mylan
  • National Cancer Institute
  • Nestlé Health Sciences
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • Novartis
  • ONO Pharmaceuticals
  • Onyx Pharmaceuticals (owned by Amgen)
  • Pfizer
  • Pharmstandard
  • Prometheus Laboratories
  • Roche
  • Syndax Pharmaceuticals
  • Tracon Pharma
  • TVAX Biomedical
  • United Nations
  • WILEX AG
  • Wyeth
Back to Top